Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1990 1
1995 1
2005 3
2006 2
2007 4
2008 2
2009 4
2010 8
2011 11
2012 11
2013 14
2014 12
2015 14
2016 9
2017 3
2018 6
2019 5
2020 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Familial Gastric Cancers.
Setia N, Clark JW, Duda DG, Hong TS, Kwak EL, Mullen JT, Lauwers GY. Setia N, et al. Among authors: kwak el. Oncologist. 2015 Dec;20(12):1365-77. doi: 10.1634/theoncologist.2015-0205. Epub 2015 Sep 30. Oncologist. 2015. PMID: 26424758 Free PMC article. Review.
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Murphy JE, et al. Among authors: kwak el. JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329. JAMA Oncol. 2018. PMID: 29800971 Free PMC article. Clinical Trial.
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Hong TS, et al. Among authors: kwak el. J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14. J Clin Oncol. 2016. PMID: 26668346 Free PMC article. Clinical Trial.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, Maur M, Hui R, Soo RA, Chiu J, Zhang T, Ma B, Kyi C, Tan DS, Cassier PA, Sarantopoulos J, Weickhardt A, Carvajal RD, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Rispoli L, Samant TS, Chowdhury NR, Gusenleitner D, Kwak EL, Askoxylakis V, De Braud F. Lin CC, et al. Among authors: kwak el. Oncoimmunology. 2023 Dec 20;13(1):2290787. doi: 10.1080/2162402X.2023.2290787. eCollection 2024. Oncoimmunology. 2023. PMID: 38170160 Free PMC article. Clinical Trial.
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS. Schöffski P, et al. Among authors: kwak el. J Immunother Cancer. 2022 Feb;10(2):e003776. doi: 10.1136/jitc-2021-003776. J Immunother Cancer. 2022. PMID: 35217575 Free PMC article. Clinical Trial.
Targeted inhibition in tumors with ALK dependency.
Kwak EL, Clark JW, Shaw AT. Kwak EL, et al. Lung Cancer (Auckl). 2013 Jan 9;4:1-8. doi: 10.2147/LCTT.S16313. eCollection 2013. Lung Cancer (Auckl). 2013. PMID: 28210129 Free PMC article. Review.
Targeted agents: the rules of combination.
Kwak EL, Clark JW, Chabner B. Kwak EL, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5232-7. doi: 10.1158/1078-0432.CCR-07-1385. Clin Cancer Res. 2007. PMID: 17875749 Review.
96 results